| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 30 | 2019 | 462 | 2.170 |
Why?
|
| Breast Neoplasms | 17 | 2019 | 759 | 1.180 |
Why?
|
| Colorectal Neoplasms | 4 | 2020 | 222 | 0.690 |
Why?
|
| Receptor, erbB-2 | 6 | 2019 | 65 | 0.670 |
Why?
|
| Lung Neoplasms | 11 | 2013 | 409 | 0.640 |
Why?
|
| Colonic Neoplasms | 6 | 2018 | 73 | 0.600 |
Why?
|
| Middle Aged | 56 | 2020 | 11949 | 0.500 |
Why?
|
| Adenocarcinoma | 6 | 2015 | 315 | 0.460 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2010 | 101 | 0.450 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2018 | 370 | 0.440 |
Why?
|
| Chemotherapy, Adjuvant | 18 | 2019 | 191 | 0.430 |
Why?
|
| Tamoxifen | 6 | 2011 | 56 | 0.410 |
Why?
|
| Aged | 44 | 2020 | 10398 | 0.410 |
Why?
|
| Female | 54 | 2020 | 20126 | 0.380 |
Why?
|
| Disease-Free Survival | 17 | 2019 | 320 | 0.360 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2015 | 40 | 0.360 |
Why?
|
| Ethmoid Sinusitis | 1 | 2010 | 1 | 0.360 |
Why?
|
| Maxillary Sinusitis | 1 | 2010 | 1 | 0.360 |
Why?
|
| Rhinitis | 1 | 2010 | 12 | 0.360 |
Why?
|
| Doxorubicin | 11 | 2019 | 79 | 0.350 |
Why?
|
| Cyclophosphamide | 10 | 2019 | 37 | 0.350 |
Why?
|
| Catheterization | 1 | 2010 | 59 | 0.350 |
Why?
|
| Quality of Life | 11 | 2017 | 915 | 0.340 |
Why?
|
| Neoplasms | 6 | 2018 | 695 | 0.340 |
Why?
|
| Aged, 80 and over | 25 | 2018 | 4050 | 0.330 |
Why?
|
| Humans | 59 | 2020 | 32297 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 7 | 2010 | 250 | 0.310 |
Why?
|
| Adult | 33 | 2018 | 9467 | 0.290 |
Why?
|
| Carcinoma, Small Cell | 4 | 2007 | 25 | 0.280 |
Why?
|
| Male | 40 | 2020 | 19488 | 0.280 |
Why?
|
| Treatment Outcome | 20 | 2015 | 3358 | 0.280 |
Why?
|
| Fatigue | 5 | 2014 | 85 | 0.250 |
Why?
|
| Neoplasm Staging | 13 | 2013 | 459 | 0.250 |
Why?
|
| Prospective Studies | 10 | 2020 | 2274 | 0.250 |
Why?
|
| Drug Administration Schedule | 12 | 2013 | 279 | 0.240 |
Why?
|
| Antineoplastic Agents | 6 | 2009 | 611 | 0.230 |
Why?
|
| Clinical Trials as Topic | 3 | 2018 | 316 | 0.230 |
Why?
|
| Quinazolines | 3 | 2013 | 38 | 0.220 |
Why?
|
| Patient Selection | 3 | 2010 | 289 | 0.210 |
Why?
|
| Survival Analysis | 10 | 2020 | 491 | 0.200 |
Why?
|
| Paclitaxel | 8 | 2017 | 67 | 0.200 |
Why?
|
| Taxoids | 6 | 2013 | 59 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2009 | 154 | 0.200 |
Why?
|
| Rectal Neoplasms | 2 | 2015 | 18 | 0.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2013 | 24 | 0.190 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2010 | 9 | 0.180 |
Why?
|
| Leukemia | 1 | 2020 | 40 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2013 | 180 | 0.180 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2010 | 34 | 0.180 |
Why?
|
| Deoxycytidine | 5 | 2013 | 68 | 0.180 |
Why?
|
| Rural Population | 1 | 2002 | 274 | 0.180 |
Why?
|
| Nausea | 4 | 2010 | 54 | 0.180 |
Why?
|
| Exercise | 2 | 2019 | 655 | 0.160 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2018 | 1 | 0.160 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 10 | 0.160 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2010 | 25 | 0.160 |
Why?
|
| Carboplatin | 8 | 2013 | 48 | 0.160 |
Why?
|
| Follow-Up Studies | 9 | 2018 | 2296 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2010 | 114 | 0.150 |
Why?
|
| Dietary Fats | 1 | 2018 | 110 | 0.150 |
Why?
|
| Mutation | 2 | 2010 | 503 | 0.150 |
Why?
|
| Cardiovascular System | 1 | 2017 | 45 | 0.150 |
Why?
|
| Kidney Neoplasms | 2 | 2010 | 201 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2009 | 129 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2018 | 36 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 2 | 2013 | 67 | 0.140 |
Why?
|
| Thromboembolism | 3 | 2010 | 35 | 0.130 |
Why?
|
| Organoplatinum Compounds | 4 | 2010 | 47 | 0.130 |
Why?
|
| Yoga | 1 | 2014 | 49 | 0.120 |
Why?
|
| Amenorrhea | 2 | 2011 | 5 | 0.120 |
Why?
|
| Receptors, Estrogen | 3 | 2015 | 103 | 0.120 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2013 | 21 | 0.120 |
Why?
|
| Feces | 1 | 2013 | 36 | 0.110 |
Why?
|
| Lymphatic Metastasis | 4 | 2017 | 172 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 85 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2020 | 696 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2013 | 17 | 0.110 |
Why?
|
| Hypertension | 2 | 2018 | 972 | 0.110 |
Why?
|
| Survival Rate | 5 | 2018 | 894 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 4 | 2019 | 196 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 87 | 0.100 |
Why?
|
| Fluorouracil | 5 | 2012 | 82 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2014 | 259 | 0.100 |
Why?
|
| Interferon-alpha | 2 | 2010 | 71 | 0.100 |
Why?
|
| Prostatic Neoplasms | 2 | 2010 | 492 | 0.100 |
Why?
|
| Risk Factors | 7 | 2019 | 3876 | 0.100 |
Why?
|
| Menstruation | 1 | 2011 | 5 | 0.100 |
Why?
|
| ras Proteins | 1 | 2010 | 10 | 0.090 |
Why?
|
| Factor V | 1 | 2010 | 7 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2020 | 1832 | 0.090 |
Why?
|
| Prognosis | 5 | 2018 | 1523 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 18 | 0.090 |
Why?
|
| Maxillary Sinus | 1 | 2010 | 7 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 94 | 0.090 |
Why?
|
| Furans | 1 | 2009 | 3 | 0.090 |
Why?
|
| Ketones | 1 | 2009 | 11 | 0.090 |
Why?
|
| Disease Progression | 4 | 2019 | 618 | 0.090 |
Why?
|
| Infusions, Intravenous | 5 | 2007 | 100 | 0.090 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2010 | 47 | 0.090 |
Why?
|
| Urologic Neoplasms | 1 | 2009 | 14 | 0.090 |
Why?
|
| Endoscopy | 1 | 2010 | 57 | 0.090 |
Why?
|
| Neutropenia | 4 | 2013 | 30 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2010 | 124 | 0.080 |
Why?
|
| Estrogens | 1 | 2010 | 174 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2009 | 69 | 0.080 |
Why?
|
| Leucovorin | 4 | 2010 | 25 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 142 | 0.080 |
Why?
|
| United States | 6 | 2019 | 3983 | 0.080 |
Why?
|
| Camptothecin | 4 | 2013 | 53 | 0.080 |
Why?
|
| Awareness | 1 | 2008 | 29 | 0.080 |
Why?
|
| Androstadienes | 1 | 2008 | 21 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2010 | 406 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2010 | 218 | 0.080 |
Why?
|
| Confidence Intervals | 4 | 2013 | 150 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 40 | 0.080 |
Why?
|
| Indoles | 1 | 2008 | 60 | 0.080 |
Why?
|
| Cisplatin | 4 | 2013 | 77 | 0.080 |
Why?
|
| Pyrroles | 1 | 2008 | 57 | 0.070 |
Why?
|
| Methylphenidate | 1 | 2007 | 37 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2006 | 8 | 0.070 |
Why?
|
| Pyrazines | 1 | 2006 | 14 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 75 | 0.070 |
Why?
|
| Heart Failure | 1 | 2012 | 630 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2006 | 35 | 0.070 |
Why?
|
| Time Factors | 5 | 2013 | 2181 | 0.070 |
Why?
|
| Guanine | 1 | 2005 | 15 | 0.070 |
Why?
|
| Glutamates | 1 | 2005 | 11 | 0.070 |
Why?
|
| Logistic Models | 3 | 2013 | 788 | 0.060 |
Why?
|
| European Continental Ancestry Group | 1 | 2010 | 1180 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2013 | 480 | 0.060 |
Why?
|
| Cachexia | 1 | 2004 | 7 | 0.060 |
Why?
|
| Fish Oils | 1 | 2004 | 35 | 0.060 |
Why?
|
| Remission Induction | 3 | 2010 | 84 | 0.060 |
Why?
|
| Mastectomy | 2 | 2015 | 65 | 0.060 |
Why?
|
| Complementary Therapies | 1 | 2005 | 79 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2018 | 110 | 0.060 |
Why?
|
| Finasteride | 1 | 2003 | 14 | 0.060 |
Why?
|
| Antiemetics | 1 | 2003 | 6 | 0.060 |
Why?
|
| Vomiting | 1 | 2003 | 25 | 0.060 |
Why?
|
| Serotonin | 1 | 2003 | 37 | 0.060 |
Why?
|
| Cognition | 1 | 2007 | 551 | 0.060 |
Why?
|
| Alprostadil | 1 | 2002 | 2 | 0.050 |
Why?
|
| Misoprostol | 1 | 2002 | 5 | 0.050 |
Why?
|
| Pharynx | 1 | 2002 | 13 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 326 | 0.050 |
Why?
|
| Mastectomy, Segmental | 2 | 2013 | 27 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2002 | 20 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 3 | 2007 | 60 | 0.050 |
Why?
|
| Mouth Neoplasms | 1 | 2002 | 18 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2002 | 31 | 0.050 |
Why?
|
| African Americans | 1 | 2010 | 1443 | 0.050 |
Why?
|
| Neoplasm Metastasis | 3 | 2009 | 222 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2010 | 550 | 0.050 |
Why?
|
| Receptors, Progesterone | 2 | 2015 | 63 | 0.050 |
Why?
|
| Canada | 2 | 2013 | 56 | 0.050 |
Why?
|
| Age Factors | 2 | 2015 | 1204 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 638 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2009 | 567 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 262 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 302 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 41 | 0.040 |
Why?
|
| Incidence | 3 | 2010 | 1207 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 84 | 0.040 |
Why?
|
| Etoposide | 2 | 2013 | 34 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 28 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2013 | 911 | 0.040 |
Why?
|
| Cataract | 2 | 2010 | 10 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2009 | 185 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 545 | 0.040 |
Why?
|
| Endometrial Neoplasms | 2 | 2010 | 44 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 82 | 0.040 |
Why?
|
| Energy Intake | 1 | 2018 | 128 | 0.040 |
Why?
|
| Risk | 2 | 2010 | 325 | 0.040 |
Why?
|
| Myocardial Ischemia | 2 | 2010 | 109 | 0.040 |
Why?
|
| North Carolina | 1 | 2002 | 1520 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2007 | 95 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 511 | 0.040 |
Why?
|
| Probability | 2 | 2006 | 160 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2017 | 171 | 0.030 |
Why?
|
| Research Design | 2 | 2010 | 313 | 0.030 |
Why?
|
| Cause of Death | 2 | 2008 | 244 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2006 | 77 | 0.030 |
Why?
|
| Pain | 2 | 2009 | 305 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 560 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2007 | 470 | 0.030 |
Why?
|
| Urination Disorders | 1 | 2015 | 6 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 264 | 0.030 |
Why?
|
| Perineum | 1 | 2015 | 18 | 0.030 |
Why?
|
| Anal Canal | 1 | 2015 | 20 | 0.030 |
Why?
|
| Body Image | 1 | 2015 | 18 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2015 | 13 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 43 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 675 | 0.030 |
Why?
|
| Abdomen | 1 | 2015 | 45 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 849 | 0.030 |
Why?
|
| Gene Expression | 1 | 2015 | 345 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 926 | 0.030 |
Why?
|
| Fractures, Bone | 2 | 2006 | 157 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2013 | 11 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 28 | 0.030 |
Why?
|
| Physician-Patient Relations | 2 | 2006 | 188 | 0.030 |
Why?
|
| Esophagitis | 1 | 2013 | 5 | 0.030 |
Why?
|
| Dehydration | 1 | 2013 | 9 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 131 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 2012 | 8 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 301 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 163 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2012 | 176 | 0.020 |
Why?
|
| Southwestern United States | 1 | 2010 | 3 | 0.020 |
Why?
|
| Vidarabine | 1 | 2010 | 6 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 14 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 25 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2010 | 38 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 15 | 0.020 |
Why?
|
| Fractures, Spontaneous | 1 | 2010 | 16 | 0.020 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2010 | 11 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2011 | 106 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2006 | 1447 | 0.020 |
Why?
|
| Anemia | 1 | 2010 | 60 | 0.020 |
Why?
|
| Premenopause | 1 | 2010 | 41 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2010 | 49 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 74 | 0.020 |
Why?
|
| Uterus | 1 | 2010 | 93 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 137 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2015 | 788 | 0.020 |
Why?
|
| Urothelium | 1 | 2009 | 55 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 134 | 0.020 |
Why?
|
| Diarrhea | 1 | 2009 | 60 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 42 | 0.020 |
Why?
|
| Stomatitis | 1 | 2008 | 18 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2007 | 33 | 0.020 |
Why?
|
| Perception | 1 | 2008 | 98 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2007 | 28 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 759 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 986 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 294 | 0.020 |
Why?
|
| Topotecan | 1 | 2006 | 17 | 0.020 |
Why?
|
| Levamisole | 1 | 2006 | 2 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2007 | 134 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 79 | 0.020 |
Why?
|
| Thalidomide | 1 | 2006 | 31 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 493 | 0.020 |
Why?
|
| Recurrence | 1 | 2007 | 266 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 2006 | 27 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2008 | 171 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2006 | 10 | 0.020 |
Why?
|
| New York | 1 | 2006 | 22 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 227 | 0.020 |
Why?
|
| Thrombosis | 1 | 2006 | 72 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 112 | 0.020 |
Why?
|
| Vincristine | 1 | 2005 | 18 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2005 | 57 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2006 | 160 | 0.020 |
Why?
|
| Prealbumin | 1 | 2004 | 9 | 0.020 |
Why?
|
| Capsules | 1 | 2004 | 15 | 0.020 |
Why?
|
| Communication | 1 | 2006 | 140 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2004 | 56 | 0.010 |
Why?
|
| Weight Gain | 1 | 2004 | 114 | 0.010 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 1 | 2003 | 4 | 0.010 |
Why?
|
| Receptors, Serotonin | 1 | 2003 | 7 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 64 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2626 | 0.010 |
Why?
|
| Morbidity | 1 | 2003 | 98 | 0.010 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2002 | 2 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 2002 | 15 | 0.010 |
Why?
|
| Prostate | 1 | 2003 | 74 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2004 | 184 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 273 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 1522 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 585 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2005 | 3514 | 0.010 |
Why?
|